Forcaltonin
Withdrawn
This medicine's authorisation has been withdrawn
recombinant salmon calcitonin
MedicineHumanWithdrawn
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Forcaltonin has been withdrawn at the request of the marketing authorisation holder.
Product information
Latest procedure affecting product information:
IA/0015
20/11/2008
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Forcaltonin
- Active substance
- Recombinant salmon calcitonin
- International non-proprietary name (INN) or common name
- recombinant salmon calcitonin
- Therapeutic area (MeSH)
- Hypercalcemia
- Osteitis Deformans
- Bone Resorption
- Anatomical therapeutic chemical (ATC) code
- H05BA01
Pharmacotherapeutic group
Calcium homeostasisTherapeutic indication
Calcitonin is indicated for:
Prevention of acute bone loss due to sudden immobilisation such as in patients with recent
osteoporotic fractures
Paget's disease
Hypercalcaemia of malignancy
Topics
This page was last updated on